Rubella – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Tue, 23 Jun 2026 04:07:51 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Rubella – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Long‑term immunity after a 6‑month‑old MMR vaccine (live attenuated) in infants: follow‑up of antibody levels 1‑3 years after routine vaccination https://clinicaltrials.eu/trial/long-term-immunity-after-early-measles-combinations-with-mumps-and-rubella-live-attenuated-vaccine-at-6-months-in-children/ Wed, 17 Jun 2026 04:03:08 +0000 https://clinicaltrials.eu/trial/long-term-immunity-after-early-measles-combinations-with-mumps-and-rubella-live-attenuated-vaccine-at-6-months-in-children/ The study looks at preventing measles, mumps, and rubella by giving a live‑attenuated vaccine called Measles-mumps-rubella vaccine (MMR) that is identified by the code name PHF00231MIG. It is administered as a small intramuscular injection when infants are 6 months old, while a comparable group receives a placebo for comparison.

The purpose is to determine whether early vaccination changes how strong the immune protection is later, measured by the amount of neutralising antibodies against measles several years after the routine dose given at age 4. Children are followed for up to three years after that routine dose, and blood samples are tested using a plaque-reduction neutralisation test and also to assess levels of IgG, a protein that shows immune memory. The study follows each child through the early vaccination, the routine dose, and the later check‑ups without requiring special procedures beyond routine clinic visits.

]]>